We have hints that DOTATATE-derived therapeutic agents may prove useful in head and neck paragangliomas and meningiomas, as they are in the remainder of the body, and that FAP-targeted agents may prove useful in multiple cancers, such as undifferentiated thyroid cancer. This evidence concerns the gene FAP and head and neck paraganglioma.